Highly efficient inhibition of human immunodeficiency virus type 1 reverse transcriptase by aptamers functionalized gold nanoparticles. 2013

Yen-Chun Shiang, and Chung-Mao Ou, and Shih-Ju Chen, and Ting-Yu Ou, and Han-Jia Lin, and Chih-Ching Huang, and Huan-Tsung Chang
Department of Chemistry, National Taiwan University, 1, Section 4, Roosevelt Road, Taipei 10617, Taiwan.

We have developed aptamer (Apt)-conjugated gold nanoparticles (Apt-Au NPs, 13 nm in diameter) as highly effective inhibitors for human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT). Two Apts, RT1t49 (Aptpol) and ODN 93 (AptRH), which recognize the polymerase and RNase H regions of HIV-1 RT, are used to conjugate Au NPs to prepare Aptpol-Au NPs and AptRH-Au NPs, respectively. In addition to DNA sequence, the surface density of the aptamers on Au NPs (nApt-Au NPs; n is the number of aptamer molecules on each Au NP) and the linker length number (Tm; m is the base number of the deoxythymidine linker) between the aptamer and Au NPs play important roles in determining their inhibition activity. A HIV-lentiviral vector-based antiviral assay has been applied to determine the inhibitory effect of aptamers or Apt-Au NPs on the early stages of their replication cycle. The nuclease-stable G-quadruplex structure of 40AptRH-T45-Au NPs shows inhibitory efficiency in the retroviral replication cycle with a decreasing infectivity (40.2%).

UI MeSH Term Description Entries
D006046 Gold A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D052157 Aptamers, Nucleotide Nucleotide sequences, generated by iterative rounds of SELEX APTAMER TECHNIQUE, that bind to a target molecule specifically and with high affinity. DNA Aptamer,DNA Aptamers,RNA Aptamers,Rna Aptamer,Nucleotide Aptamers,Oligonucleotide Ligands, DNA,Oligonucleotide Ligands, RNA,Aptamer, DNA,Aptamer, Rna,Aptamers, DNA,Aptamers, RNA,DNA Oligonucleotide Ligands,RNA Oligonucleotide Ligands
D053768 Metal Nanoparticles Nanoparticles produced from metals whose uses include biosensors, optics, and catalysts. In biomedical applications the particles frequently involve the noble metals, especially gold and silver. Metal Nanocrystals,Metallic Nanocrystals,Metallic Nanoparticles,Metal Nanocrystal,Metal Nanoparticle,Metallic Nanocrystal,Metallic Nanoparticle,Nanocrystal, Metal,Nanocrystal, Metallic,Nanocrystals, Metal,Nanocrystals, Metallic,Nanoparticle, Metal,Nanoparticle, Metallic,Nanoparticles, Metal,Nanoparticles, Metallic
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D056945 Hep G2 Cells A human liver tumor cell line used to study a variety of liver-specific metabolic functions. Cell Line, Hep G2,Cell Line, Hepatoblastoma G2,Hep G2 Cell Line,HepG2 Cells,Hepatoblastoma G2 Cell Line,Cell, Hep G2,Cell, HepG2,Cells, Hep G2,Cells, HepG2,Hep G2 Cell,HepG2 Cell
D057809 HEK293 Cells A cell line generated from human embryonic kidney cells that were transformed with human adenovirus type 5. 293T Cells,HEK 293 Cell Line,HEK 293 Cells,Human Embryonic Kidney Cell Line 293,Human Kidney Cell Line 293,293 Cell, HEK,293 Cells, HEK,293T Cell,Cell, 293T,Cell, HEK 293,Cell, HEK293,Cells, 293T,Cells, HEK 293,Cells, HEK293,HEK 293 Cell,HEK293 Cell
D058726 Nanoconjugates Tailored macromolecules harboring covalently-bound biologically active modules that target specific tissues and cells. The active modules or functional groups can include drugs, prodrugs, antibodies, and oligonucleotides, which can act synergistically and be multitargeting. Nanoconjugate

Related Publications

Yen-Chun Shiang, and Chung-Mao Ou, and Shih-Ju Chen, and Ting-Yu Ou, and Han-Jia Lin, and Chih-Ching Huang, and Huan-Tsung Chang
September 2004, Chembiochem : a European journal of chemical biology,
Yen-Chun Shiang, and Chung-Mao Ou, and Shih-Ju Chen, and Ting-Yu Ou, and Han-Jia Lin, and Chih-Ching Huang, and Huan-Tsung Chang
February 1996, Biological chemistry Hoppe-Seyler,
Yen-Chun Shiang, and Chung-Mao Ou, and Shih-Ju Chen, and Ting-Yu Ou, and Han-Jia Lin, and Chih-Ching Huang, and Huan-Tsung Chang
July 1991, Proceedings of the National Academy of Sciences of the United States of America,
Yen-Chun Shiang, and Chung-Mao Ou, and Shih-Ju Chen, and Ting-Yu Ou, and Han-Jia Lin, and Chih-Ching Huang, and Huan-Tsung Chang
June 2006, Biochemistry,
Yen-Chun Shiang, and Chung-Mao Ou, and Shih-Ju Chen, and Ting-Yu Ou, and Han-Jia Lin, and Chih-Ching Huang, and Huan-Tsung Chang
July 2014, Antimicrobial agents and chemotherapy,
Yen-Chun Shiang, and Chung-Mao Ou, and Shih-Ju Chen, and Ting-Yu Ou, and Han-Jia Lin, and Chih-Ching Huang, and Huan-Tsung Chang
June 1992, Biochemical pharmacology,
Yen-Chun Shiang, and Chung-Mao Ou, and Shih-Ju Chen, and Ting-Yu Ou, and Han-Jia Lin, and Chih-Ching Huang, and Huan-Tsung Chang
March 1993, Journal of clinical microbiology,
Yen-Chun Shiang, and Chung-Mao Ou, and Shih-Ju Chen, and Ting-Yu Ou, and Han-Jia Lin, and Chih-Ching Huang, and Huan-Tsung Chang
November 1996, The Journal of pharmacology and experimental therapeutics,
Yen-Chun Shiang, and Chung-Mao Ou, and Shih-Ju Chen, and Ting-Yu Ou, and Han-Jia Lin, and Chih-Ching Huang, and Huan-Tsung Chang
August 1990, FEBS letters,
Yen-Chun Shiang, and Chung-Mao Ou, and Shih-Ju Chen, and Ting-Yu Ou, and Han-Jia Lin, and Chih-Ching Huang, and Huan-Tsung Chang
July 2002, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!